Labcorp Holdings (FRA:N6B) Cyclically Adjusted Revenue per Share: €144.83 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N6B Labcorp Holdings Inc FRA:N6B
78 GF Score
Price €270.00
GF Value €242.31
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Labcorp Holdings Cyclically Adjusted Revenue per Share?

Labcorp Holdings FRA:N6B 78 Cyclically Adjusted Revenue per Share is €144.83 as of Jun. 2026. GuruFocus rates FRA:N6B with a GF Score™ of 78/100 and a GF Value™ of €242.31 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Labcorp Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was €39.134. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €144.83 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Labcorp Holdings's average Cyclically Adjusted Revenue Growth Rate was 6.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Labcorp Holdings was 12.80% per year. The lowest was -2.30% per year. And the median was 9.25% per year.

As of today (2026-09-16), Labcorp Holdings's current stock price is €270.00. Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €144.83. Labcorp Holdings's Cyclically Adjusted PS Ratio of today is 1.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Labcorp Holdings was 2.52. The lowest was 1.08. And the median was 1.78.


Labcorp Holdings  (FRA:N6B) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Labcorp Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=270.00/144.827
=1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Labcorp Holdings was 2.52. The lowest was 1.08. And the median was 1.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Labcorp Holdings Cyclically Adjusted Revenue per Share Related Terms


Labcorp Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Labcorp Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labcorp Holdings Cyclically Adjusted Revenue per Share Chart

Labcorp Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.34 107.95 118.14 128.75 136.29

Labcorp Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.46 138.28 138.75 142.17 144.83

FRA:N6B vs DGX, MTD, ILMN: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Labcorp Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:N6B
78GF Score
Labcorp Holdings Inc FRA:N6B
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labcorp Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Labcorp Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=39.134/333.9520*333.9520
=39.134

Current CPI (Jun. 2026) = 333.9520.

Labcorp Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 20.626 241.428 28.531
201612 21.427 241.432 29.638
201703 21.713 243.801 29.742
201706 22.154 244.955 30.203
201709 21.538 246.819 29.141
201712 22.479 246.524 30.451
201803 22.414 249.554 29.994
201806 23.357 251.989 30.954
201809 23.702 252.439 31.355
201812 24.139 251.233 32.087
201903 24.706 254.202 32.457
201906 25.958 256.143 33.843
201909 26.795 256.759 34.851
201912 27.220 256.974 35.374
202003 26.370 258.115 34.118
202006 25.735 257.797 33.337
202009 34.000 260.280 43.624
202012 38.311 260.474 49.118
202103 35.076 264.877 44.223
202106 32.467 271.696 39.906
202109 35.492 274.310 43.209
202112 36.888 278.802 44.185
202203 36.980 287.504 42.954
202206 29.588 296.311 33.347
202209 31.379 296.808 35.306
202212 40.497 296.797 45.567
202303 31.812 301.836 35.197
202306 31.319 305.109 34.280
202309 32.297 307.789 35.042
202312 33.230 306.746 36.177
202403 34.555 312.332 36.947
202406 35.489 314.175 37.723
202409 35.398 315.301 37.492
202412 37.069 315.605 39.224
202503 37.703 319.799 39.372
202506 37.092 322.561 38.402
202509 36.431 324.800 37.458
202512 36.306 324.054 37.415
202603 36.475 330.213 36.888
202606 39.134 333.952 39.134

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €144.83 mean?
Labcorp Holdings (FRA:N6B) has a Cyclically Adjusted Revenue per Share of €144.83 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Labcorp Holdings and its competitors.
Is Labcorp Holdings' Cyclically Adjusted Revenue per Share too high?
Labcorp Holdings' current Cyclically Adjusted Revenue per Share is €144.83. Overall, Labcorp Holdings has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Cyclically Adjusted Revenue per Share compare to DGX and MTD?
Labcorp Holdings' Cyclically Adjusted Revenue per Share of €144.83 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Labcorp Holdings and its competitors. Labcorp Holdings's current Cyclically Adjusted Revenue per Share is €144.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (FRA:N6B) is currently considered Modestly Overvalued. The stock's GF Value™ is €242.31, compared to a current price of €270.00 — trading 11.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €144.83. Labcorp Holdings' overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Labcorp Holdings (FRA:N6B), the current Cyclically Adjusted Revenue per Share is €144.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labcorp Holdings (FRA:N6B) Overvalued in 2026?

Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued. The current stock price of €270.00 is trading 11.4% above its estimated GF Value™ of €242.31. GuruFocus considers Labcorp Holdings to be Modestly Overvalued.

Key valuation signals for FRA:N6B:

  • Cyclically Adjusted Revenue per Share: €144.83
  • GF Value™: €242.31 vs. price of €270.00 (11.4% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the FRA:N6B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labcorp Holdings Business Description

Other Exchanges LH:USA0JSY:UKN6B:Germany
Address 358 South Main Street, Burlington, NC, USA, 27215
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
78GF Score

Get the complete analysis for FRA:N6B

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€270.00
Price
€242.31
GF Value